Skip to content

Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers

An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft- C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers

Status
Terminated
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04134143
Enrollment
6
Registered
2019-10-22
Start date
2019-11-07
Completion date
2020-12-30
Last updated
2021-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetic Foot Ulcer, Non-healing Wound

Brief summary

Some people with diabetes get foot ulcers that do not heal. These ulcers can get infected and cause other medical problems. Five patients with these foot ulcers volunteered to participate in the first part of this study (C9T12015, NCT02657876). They are called Cohort 1 in this registration. Cohort 1 received one application (piece) of an experimental skin tissue to make sure it was safe. This study will extend the safety test of the experimental skin tissue. It will find out if it is safe to use more than once to cover non-healing ulcers. This extension will include two more groups, Cohort 2 and Cohort 3. Cohort 2 may get up to 5 applications. Cohort 3 may get up to 10 applications. The number of applications will depend on how well the wound is healing. Participants will be in the study up to one year.

Interventions

A round patch of experimental skin tissue that the doctor applies over the ulcer

Sponsors

Stratatech, a Mallinckrodt Company
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Cohort 2 will begin when the study starts, and after the safety monitoring board approves progression to the next cohort, Cohort 3 will begin.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Volunteers will be consented. Then there will be a run-in period for the doctor to run some tests. If the tests show the study would be good for the patient, the doctor will enroll them as participants in the trial. Inclusion Criteria: To be considered for inclusion, a participant: * Agrees to practice birth control for the duration of the study * Has documented Type 1 or Type 2 diabetes and an HbA1C score of 10 or below * Has protocol-defined sufficient blood pressure and flow to the foot * Has stable medications for 2 weeks before treatment (other than diabetes medications or antibiotics) * Is able and willing to attend scheduled visits and comply with study procedures * If a smoker, agrees to try quitting and will accept counseling for it (Cohorts 2 and 3 only) * Has documented informed consent for study enrollment * Has had an uninfected, appropriately-sized diabetic ulcer on the foot for at least 4 weeks but not more than 1 year

Exclusion criteria

The doctor may not consider for inclusion a participant who: * Is pregnant, nursing, or a prisoner * Has had osteomyelitis in the foot with the ulcer in the last 30 days * Has a history of poor compliance * Has received drugs or therapies not allowed per protocol * Has used an investigational product within the last 60 days * Has ever received therapy for the study ulcer with any cell and/or tissue product (CTP) * Has a study ulcer in a condition not appropriate for the study * Has a medical condition or history that, per protocol or in the opinion of the study doctor, might put the safety of the participant in danger

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with adverse events at Week 12at Week 12Clinically significant vital signs, infection, blood chemistry, hematology and immunological evaluations are recorded as adverse events
Number of participants with adverse events through study completionat approximately 12 monthsClinically significant vital signs, infection, blood chemistry, hematology and immunological evaluations are recorded as adverse events

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026